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Transferrin receptor 2 (TFR2), a protein homologous to the cell iron importer TFR1, is
expressed in the liver and erythroid cells and is reported to bind diferric transferrin,
although at lower afﬁnity than TFR1. TFR2 gene is mutated in type 3 hemochromatosis, a
disorder characterized by iron overload and inability to upregulate hepcidin in response to
iron. Liver TFR2 is considered a sensor of diferric transferrin, possibly in a complex with
hemochromatosis protein. In erythroid cells TFR2 is a partner of erythropoietin receptor
(EPOR) and stabilizes the receptor on the cell surface. However, Tfr2 null mice as well
as TFR2 hemochromatosis patients do not show defective erythropoiesis and tolerate
repeated phlebotomy. The iron deﬁcient Tfr2-Tmprss6 double knock out mice have higher
red cells count and more severe microcytosis than the liver-speciﬁc Tfr2 and Tmprss6
double knock out mice. TFR2 in the bone marrow might be a sensor of iron deﬁciency
that protects against excessive microcytosis in a way that involves EPOR, although the
mechanisms remain to be worked out.
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THE SECOND TRANSFERRIN RECEPTOR
Transferrin receptor 2 (TFR2) is a type II transmembrane gly-
coprotein, member of the TFR family and homologous to TFR1,
which provides iron to the cell by internalization of the transferrin-
iron complex through receptor-mediated endocytosis. TFR2 was
cloned during a project aimed at isolating genes encoding new
transcription factors (Kawabata et al., 1999). The TFR2 gene
comprises 18 exons and maps to chromosome 7q22 in close
proximity to the EPO gene. Two TFR2 isoforms have been
described: the alpha isoform, corresponding to all 18 exons,
encodes a protein of about 89 kDa in its unglycosylated form.
The beta form, which results from an alternative splicing, lacks
exons 1–3, and has 142 additional nucleotides in its ﬁrst exon
(exon 4 of the alpha form). The resulting protein lacks the
cytoplasmic and the transmembrane domain (Kawabata et al.,
1999) and its function remains unknown. The alpha protein
encompasses 801 amino acids and, as TFR1, has a short cyto-
plasmic tail that contains a consensus sequence for endocytosis,
a transmembrane domain and a large extracellular region that
comprises a protease-associated domain and two RGD motifs
(only one is present in TFR1), that bind diferric transferrin.
TFR2 differs from TFR1 for several aspects. First, TFR1 is ubiq-
uitously expressed, whereas the expression of TFR2 is restricted
to the hepatocytes and erythroid precursors. Second, TFR1 is
post-transcriptionally regulated by iron through the iron regu-
latory proteins–iron responsive elements (IRP–IRE) interaction,
while TFR2 is not regulated by IRPs. TFR2 5′ and 3′ untrans-
lated regions do not contain IRE elements (Fleming et al., 2000);
rather TFR2 promoter shows GATA-1 as well as c-EBP-alpha
consensus sequences. Furthermore, although in transfected cells
TFR2 may uptake iron loaded transferrin (holo-TF) in trans-
fected cells, in vivo it does not rescue the embryo-lethality of
Tfr1−/− mice (Levy et al., 1999), suggesting a function distinct
from TFR1 and unrelated to iron transport. Moreover, the afﬁnity
of TFR2 for holo-TF is signiﬁcantly lower than that of TFR1 (Kd
30 nM vs. 1 nM, respectively; Kawabata et al., 2000; West et al.,
2000).
It has been reported that both TFRs bind hemochromatosis
protein (HFE) in vitro. However, crystallographic studies have
shown thatHFE binds TFR1 (Bennett et al., 2000) at the same con-
sensus sequences of diferric transferrin, implying a competition
between the two ligands. On the contrary, based on in vitro data,
binding of HFE to TFR2 and holo-Tf would occur simultaneously
at two different TFR2 sequence motifs (Gao et al., 2009).
In the liver Tfr2 expression increases during mouse develop-
ment, at variance with Tfr1, and in adult liver Tfr2 is much more
expressed than Tfr1 (Kawabata et al., 2001). Our knowledge of
the TFR2 hepatic function is still incomplete. In hepatoma cell
lines TFR2 is stabilized on cell surface by the addition of holo-
transferrin to the culture media, an effect due to the increased
protein half-life (Enns, 2001). The divergent iron-mediated reg-
ulation of the two TFRs is conﬁrmed also in vivo: while in iron
loaded mice Tfr1 is downregulated by the loss of IRP-mediated
mRNA stabilization, Tfr2 protein level is increased. In agreement
with a ligand-mediated stabilization, levels of Tfr2 protein are
decreased in the liver of hypotransferrinemic (hpx) mice (Robb
and Wessling-Resnick, 2004). Thus the major regulation of TFR2
occurs at the protein rather than at RNA level.
In cell culturemodels, TFR2 localizes in caveolarmicrodomains
(Calzolari et al., 2006), membrane structures involved in the
recruitment of receptors that can be activated by ligand binding
(Simons and Toomre, 2000). In the absence of holo-transferrin,
both TFR1 and TFR2 are internalized by clathrin-mediated endo-
cytosis (Chen et al., 2009), whereas in the presence of the ligand
only TFR2, and not TFR1, activates ERK1/2 and p38 MAPK. This
has been observed in hepatoma derived and in erythroid cells,
supporting the hypothesis that TFR2 may function as a signaling
receptor (Calzolari et al., 2006; Poli et al., 2010).
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The stabilization of TFR2 by holo-transferrin and its abil-
ity to bind HFE led to the current model in which liver TFR2,
in conjunction with HFE, represents a sensor of circulating
iron and activates hepcidin in response to elevated transfer-
rin saturation (Goswami and Andrews, 2006). In addition it
has been shown that the TFR2-HFE interaction on the hep-
atocyte surface occurs within a multiprotein complex, that in
vitro includes also the BMP-coreceptor hemojuvelin (D’Alessio
et al., 2012). If this complex activates the intracellular signal-
ing to upregulate hepcidin expression in vivo remains to be
demonstrated. In addition, the binding of TFR2 to HFE has
recently been questioned (Rishi et al., 2013) and some evidences
are in favor of a distinct function for the two HFEs. Mice
with inactivation of both Tfr2 and Hfe have a more severe
phenotype compared to single mutant animals (Wallace et al.,
2009). This occurs also in humans: patients with mutation
in TFR2 and HFE were reported to develop a severe form of
juvenile-like hemochromatosis (Pietrangelo et al., 2005). More-
over, patients with TFR2 mutations do not upregulate hepcidin
upon oral iron administration, whereas the iron response is
partially preserved in HFE patients (Girelli et al., 2011), thus
strengthening the distinct and non-overlapping role of HFE and
TFR2.
TFR2: THE GENE OF HEMOCHROMATOSIS TYPE 3
In humans inactivating mutations of TFR2 lead to hemochro-
matosis type 3 (Camaschella et al., 2000), a rare recessive disorder
characterized by iron overload, low hepcidin levels (Nemeth et al.,
2005) and inability to properly regulate hepcidin after an oral
iron challenge (Girelli et al., 2011). The disorder is quite rare
among Caucasians and occasionally reported in Japanese, with
single families identiﬁed in France, Portugal Spain and Taiwan.
Currently, less than 30 pathogenic mutations have been described
(Camaschella and Roetto, 2011). They are all rare, often private.
Some insertions cause frameshift and premature stop codon, oth-
ers are nonsense and small deletions. All the mutations are loss
of function; missense mutations prevalently affect the protein
C-terminus, especially the peptidase-like and the dimerization
domains, suggesting that these regions have important functional
roles (Camaschella and Roetto, 2011). The affected residues, usu-
ally highly conserved,might be essential for the proper folding and
protein localization, or relevant for interactionwith other proteins
or for the regulatory function of TFR2.
The type of iron overload caused by mutations in TFR2 dif-
fers from the classic type 1 HFE-hemochromatosis, because of an
earlier onset andmore severe presentation (Camaschella, 2005). A
study in patients affected by type 1 (HFE-related) or type 3 (TFR2-
related) hemochromatosis showed a different role for TFR2 and
HFE in hepcidin activation in response to a single oral iron chal-
lenge able to increase transferrin saturation: HFE patients showed
a blunted hepcidin response, whereas TFR2 patients showed no
response (Girelli et al., 2011). A similar difference in the hep-
cidin response after an acute iron loading has been observed in
Tfr2Y245X/Y245X and Hfe−/− mice (Corradini et al., 2011; Ramos
et al., 2011). These results led to the conclusion that TFR2 is
important to up-regulate hepcidin in response to transferrin
saturation.
TFR2 IN ERYTHROID CELLS
In favor of the relevance of TFR2 for the erythroid differentiation
are two genetic observations: ﬁrst, the close proximity of TFR2
and EPO genes on chromosome 7q22 that may suggest a common
regulation. Second, the results of different genome-wide associa-
tion studies: TFR2 single nucleotide polymorphisms (SNPs) have
been identiﬁed associated with erythroid quantitative traits, such
as red cell numbers, indexes and hematocrit (Ganesh et al., 2009;
Soranzo et al., 2009; Ding et al., 2012). Although this observation
could be due to an indirect effect mediated by serum iron levels,
that were notmeasured in the original studies (Ganesh et al., 2009;
Soranzo et al., 2009; Ding et al., 2012), a direct effect of TFR2 on
erythropoiesis cannot be excluded.
More recently itwas shown that in erythroid cells TFR2 is a part-
ner of erythropoietin receptor (EPOR) that stabilizes the receptor
on cell surface. TFR2 is co-expressed with EPOR during erythroid
differentiation and its maximal expression precedes that of TFR1
(Kawabata et al., 2001). TFR2 protein, that associates with EPOR
in the endoplasmic reticulum, is needed for the efﬁcient trans-
port of the receptor to the cell membrane (Forejtnikova et al.,
2010). The interaction facilitates the stabilization of EPOR, likely
contributing to EPO sensitivity and erythroid cell differentiation,
both in vitro and in vivo. However the interaction does not seem
to inﬂuence EPO binding to EPOR. In addition direct binding of
TFR2 toEPOwas excluded (Forejtnikova et al., 2010). Interestingly
TFR2 silencing in human erythroid precursors delays their ter-
minal differentiation in vitro (Forejtnikova et al., 2010). However,
which signaling pathway is activated byTFR2 is still unclear. More-
over, although TFR2 is required for efﬁcient erythropoiesis, Tfr2
null mice as well as TFR2 hemochromatosis patients do not show
defective erythropoiesis and patients tolerate repeated courses of
phlebotomy without developing anemia.
ANIMAL MODELS OF Tfr2 INACTIVATION DEVELOP IRON
OVERLOAD
The ﬁrst animal model of hemochromatosis type 3 was gener-
ated by targetedmutagenesis, introducing a premature stop codon
(Y245X; Fleming et al., 2002) in the murine Tfr2 coding sequence.
This mutation is orthologous to the mutation (Y250X) originally
detected in humans (Camaschella et al., 2000). Young (4week-old)
homozygous Y245X mutant mice had high liver iron concentra-
tion, even if maintained on a standard diet, in agreement with
the observation of early iron overload in patients. The histologi-
cal distribution of iron recapitulates features of hemochromatosis,
with the typical liver periportal accumulation and low spleen iron
stores. As in humans, heterozygous animals were normal. Later on,
several murinemodels of Tfr2 inactivation were developed (Flem-
ing et al., 2002;Wallace et al., 2007), including, among others,Tfr2
total (Tfr2−/−) and liver-speciﬁc (Tfr2 LCKO) knock-out (Wallace
et al., 2007; Roetto et al., 2010) and Tfr2-Hfe double knock-out.
All these models are characterized by low hepcidin expression
and liver iron overload of variable severity (Table 1). However,
when generated in the same genetic background,Tfr2 total knock-
out was shown to have iron overload more severe than Hfe−/−
although less severe thanHfe/Tfr2 double knock out. These obser-
vations are in agreement with the suggested distinct function of
the two proteins.
Frontiers in Pharmacology | Drug Metabolism andTransport May 2014 | Volume 5 | Article 93 | 2
Silvestri et al. Erythroid TFR2
Table 1 | Hepcidin levels, iron and hematological phenotype in the available murine models ofTfr2 inactivation.
Mouse model Hepcidin
expression
Iron phenotype Hematological
phenotype
Reference
RBC Hb
Tfr2Y 245X /Y 245X Reduced* Iron overload n.a Normal Fleming et al. (2002), Kawabata et al. (2005)
Tfr2−/− Reduced* Iron overload Normal High Roetto et al. (2010), Wallace et al. (2005)
Tfr2LCKO Reduced* Severe iron overload Normal Normal Roetto et al. (2010), Wallace et al. (2007)
Tfr2KI Normal Moderate iron overload
(old mice)
Low Low Roetto et al. (2010)
(only in young mice)
Tfr2−/−Hfe−/− Low Severe iron overload n.a n.a. Wallace et al. (2009)
Tfr2Y 245X /Y 245X Hfe−/− Very low Severe iron overload n.a n.a. Corradini et al. (2011)
Tfr2Y 245X /Y 245XTmprss6msk/msk High Iron deﬁciency High Low Lee et al. (2012)
Tfr2−/−Tmprss6−/− High Iron deﬁciency High Low Nai et al. (2014)
Tfr2LCKOTmprss6−/− Very high Iron deﬁciency High Low Nai et al. (2014)
RBC, red blood cells; Hb, hemoglobin.
*Reduced compared to the level of iron-loaded mice; n.a = not available.
A last model was generated with the M167K substitu-
tion in the Tfr2 protein (Roetto et al., 2010): this muta-
tion destroys the methionine, putative start codon of the
beta-isoform of the protein. β-Tfr2 is mostly expressed in
the spleen (Kawabata et al., 1999; Roetto et al., 2010). Inter-
estingly, the knock-in model Tfr2KI , speciﬁcally lacking the
beta-isoform, is characterized by normal transferrin satu-
ration, liver iron concentration, hepcidin and Bmp6 lev-
els but show a transient anemia at young age. In addi-
tion adult animals accumulate iron in the spleen due to
strong reduction of ferroportin mRNA, thus suggesting a
possible regulatory effect of β-Tfr2 on splenic ferroportin
expression.
ANIMAL MODELS OF Tfr2 INACTIVATION IN IRON
DEFICIENCY
Tfr2−/− mice have slightly less severe iron overload than liver-
speciﬁc (Tfr2LCKO) knock-out (Wallace et al., 2007; Roetto et al.,
2010), slightly higherHb levels (Roetto et al., 2010; Nai et al., 2014)
and moderate macrocytosis. The Tmprss6−/− mice, which have a
deletion of the hepcidin inhibitor, the serine protease Tmprss6, is
a well established model of iron deﬁciency anemia with high hep-
cidin (Du et al., 2008; Folgueras et al., 2008). Tmprss6−/−Tfr2−/−
double knock out animals develop iron deﬁciency with high hep-
cidin, a phenotype similar to Tmprss6−/− mice (Lee et al., 2012;
Nai et al., 2014) and to Tmprss6−/−Hfe−/− animals (Finberg
et al., 2011; Lee et al., 2012). In a single study some degree of
erythrocytosis were observed both in Tfr2−/− and in Hfe−/−
knock-out with deletion of Tmprss6 (Lee et al., 2012), although
results forHfe−/−Tmprss6−/− are not unequivocal (Finberg et al.,
2011).
Deleting Tmprss6 in the two hemochromatosis type 3 models,
Tfr2−/− and Tfr2LCKO mice, revealed similarities but also dif-
ferences in the hematological phenotype of the resulting double
knock-out animals (Nai et al., 2014). Both models have the same
degree of anemia, low transferrin saturation and low liver iron con-
tent (LIC), a phenotype quite similar to that of the iron deﬁcient
Tmprss6−/− (Table 1).
The modiﬁcation of the phenotype of Tfr2−/− mice with
deletion of Tmprss6 has important implications. First it indi-
cates that hepatic TFR2 is genetically upstream TMPRSS6 in the
BMP-SMAD signaling pathway, as previously shown for HFE
(Finberg et al., 2011; Lee et al., 2012). Second, it excludes that
TFR2 is a substrate of TMPRSS6, as previously observed in our
in vitro studies (Pagani, unpublished observation, 2014). Fur-
ther, it suggests that Tmprss6 is likely hyperactive in Tfr2−/−
mice with iron overload and thus its inhibition might be
effective in up-regulating hepcidin production and reducing
iron overload, as shown by the use of small interference
RNA (siRNA) or allele speciﬁc oligonucleotide (ASO) against
Tmprss6 (Guo et al., 2013; Schmidt et al., 2013) in Hfe−/−
animals.
We observed that the phenotype of Tfr2-Tmprss6 double
knock-out mice is not exactly the same of the double knock-
out for Tfr2LCKO and Tmprss6 or of Tmprss6−/− knock out
(Table 1). An increased number of red cells are observed only
in Tfr2-Tmprss6 double knock-out mice. Also, while hepcidin
levels are increased in all models as compared with wild-type ani-
mals, they are less elevated inTfr2−/−Tmprss6−/− mice compared
with the other models. It seems that some inhibitory signal low-
ers hepcidin in Tfr2−/−Tmprss6−/− mice. In principle this may
derive from the increased red cell production, exclusively present
in Tfr2−/−Tmprss6−/− mice. It is of interest that the observed
erythrocytosis is not due to enhanced erythropoietin (Epo) stimu-
lation of erythropoiesis, since Epo levels are similar and consistent
with similar degrees of anemia in all models. They are even
decreased in Tmprss6−/−Tfr2−/− (Nai et al., 2014). We specu-
late that this positive modulation of erythropoiesis might result
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from the lack of Tfr2 expression in the erythroid compartment
(Figure 1).
Recently an erythroid function for Tfr2 was independently
reported byWallace et al. (2013)whonoticed that the triple knock-
out (Tfr2−/−, Hfe−/−, Tmprss6−/−) mice have more severe iron
deﬁciency than Tmprss6−/− mice with deletion of either Hfe or
Tfr2. However, themechanismunderlining this difference remains
to be worked out.
From all the data available we concluded that Tfr2 in the ery-
throid compartment might serve to block excessive erythropoietic
expansion. If this occurs in normal conditions (Figure 1 panel A)
is difﬁcult to verify becauseTfr2 deletion leads to iron overload. In
iron overload indeed the Tfr2 erythroid function is likely masked
by the excessive iron availability that increases Hb and also Hb
content per single cell (Figure 1 panel B vs. A; Roetto et al., 2010;
(Nai et al., 2014). Tfr2 function becomes more evident in iron
FIGURE 1 | Schematic representation of Tfr2-mediated erythropoiesis
modulation. (A) in normal conditions Tfr2 and erythropoietin receptor
(EpoR) interact and localize on the cell surface and control red blood cells
production (B) Tfr2 inactivation in mice causes iron overload: mean
corpuscular hemoglobin (MCH) is enhanced (indicated by the darker red
color of the erythrocytes) due to the increased iron availability. (C)
Inactivation of Tmprss6 in Tfr2 KO mice increases the number of microcytic
erythrocytes, as indicated by the light red color of the erythrocytes.
Epo-EpoR interaction occurs in all conditions but is increased in the
absence of Tfr2 (panel B and C vs. A).
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deﬁciency, as exempliﬁed by Tmprss6−/−Tfr2−/− double knock
out mice (Figure 1 panel C).
CONCLUSION
From its identiﬁcation and cloningmore than 10 years ago (Kawa-
bata et al., 1999), the correct function of TFR2 in iron metabolism
has remained mysterious. Several different roles have been pro-
posed for this receptor: originally published as a second iron
importer, after the identiﬁcation of TFR2mutations in hemochro-
matosis patients its proposed function became that of potential
sensor of circulating iron-loaded transferrin and then of hepcidin
(co)-activator. Although counteracting iron excess in the circula-
tion remains its major function in the liver, an as well important
erythropoietic function is emerging from our and other studies
From the few available data it seems that TFR2 might serve as a
brake to avoid iron consumption in excessive erythrocyte produc-
tion in conditions of iron deﬁciency, likely within the perspective
of global body iron economy. A prevalent role of erythroid TFR2
in iron deﬁciencymight explainwhy this role is not evident inmice
nor in patients with type 3 hemochromatosis, who are iron loaded
and never experience iron deﬁciency. Further studies are needed to
clarify the molecular mechanisms that mediate the TFR2 function
in iron deﬁciency. However from now on the erythropoiesis status
should be considered when interpreting the effect of TFR2 in iron
metabolism and homeostasis.
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